Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03318939
Title Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Spectrum Pharmaceuticals, Inc
Indications

lung non-small cell carcinoma

Therapies

Poziotinib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN | BEL


No variant requirements are available.